TCM
UTHR icon

Tang Capital Management’s United Therapeutics UTHR Stock Holding History

Tang Capital Management’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-160,000
Closed -$16.2M – 19
2020
Q3 		$16.2M Sell
160,000
-40,000
-20% -$4.39M 2.92% 9
2020
Q2 		$24.2M Sell
200,000
-8,415
-4% -$947K 2.35% 8
2020
Q1 		$19.8M Buy
+208,415
New +$19.8M 2.78% 8

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Tang Capital Management's UTHR Position: Q4 2020 in Review

Tang Capital Management sold out of United Therapeutics (UTHR) in Q4 2020, closing a stake of 160,000 shares — an estimated $16.2M sold.

Tang Capital Management first reported a position in UTHR in Q1 2020 and held it in 3 quarters. The position peaked at $24.2M in Q2 2020. 356 funds tracked by Wall St. Rank hold UTHR as of Q4 2020.

  • Tang Capital Management reported no remaining United Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Tang Capital Management sold 160,000 United Therapeutics shares in Q4 2020, an estimated $16.2M.
  • Tang Capital Management first reported a position in United Therapeutics in Q1 2020 and held it in 3 quarters.
  • Tang Capital Management's United Therapeutics position peaked at $24.2M in Q2 2020.
  • 356 funds tracked by Wall St. Rank held United Therapeutics as of Q4 2020.

Based on Tang Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.